Trials / Unknown
UnknownNCT04972422
A Phase 1b Study of ZN-c3 in Chinese Subjects
A Phase 1b Study of ZN-c3 as a Single Agent in Patients With Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- Zentera Therapeutics HK Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics of ZN c3.
Detailed description
This study consists of Dose Escalation and Dose Expansion component in Chinese subjects with solid tumors, described briefly as follows: Dose Escalation: Single Agent Dose Escalation of ZN-c3 in solid tumors. Dose Expansion: Single Agent ZN-c3 in solid tumors at the RP2D dose level.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZN-c3 | ZN-c3 is a study drug |
Timeline
- Start date
- 2021-07-15
- Primary completion
- 2022-06-30
- Completion
- 2023-06-30
- First posted
- 2021-07-22
- Last updated
- 2021-09-05
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04972422. Inclusion in this directory is not an endorsement.